IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philippe G. Nantermet et al.

Serial No.: 10/573,232 Case No.: 21546YP

Group Art Unit: 1624

Examiner: Paul V. Ward

US Nat'l Filing Date: March 23, 2006

Int'l Appl'n No.: PCT/US2004/032009

Int'l Filing Date: 29 September 2004

For: BENZYLETHER AND BENZYLAMINO BETA-SECRETASE

INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S

DISEASE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

COMMUNICATION

Sir:

This is in response to the Office Action mailed October 26, 2009, and further in response to a telephone conference with Examiner Paul Ward on November 12, 2009. The undersigned thanks Examiner Ward for the courtesies extended during the teleconference.

As discussed, applicants are resending the Amendment mailed August 25, 2009. The August 25, 2009 amendment addresses the issues raised in the October 26, 2009 Office Action, and should put this application in condition for allowance.

U.S. Serial No.: 10/573,232

Case No.: 21546YP Page No.: 2

It is believed that no fees are due for this submission. If it is determined that any fees are due, the fees should be charged to Merck Deposit Account No. 13-2755.

Favorable action is earnestly solicited.

Respectfully submitted,

By /John C. Todaro/ John C. Todaro, Reg. No. 36,036 Attorney for Applicants

> MERCK & CO., Inc. P.O. Box 2000 Rahway, New Jersey 07065 Tel.: (732) 594-0125

Date: December 9, 2009